Delivery Order SPE2DB22D9353-SPE2DB26FX1KR
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,574.41 to DMS Pharmaceutical Group Inc. on August 11, 2025, for the supply of EXPAREL 266 mg/20 mL vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its Park Ridge facility with an ultimate completion date of September 2, 2025. This delivery order was issued without a set-aside designation, allowing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,107.10 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This delivery order represents a firm fixed-price contract with an ultimate completion date of September 30, 2025, and will be fulfilled from the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,659.45 to DMS Pharmaceutical Group Inc. for EXPAREL 266 mg/20 mL vials. The order was issued on September 11, 2025, with an ultimate completion date of October 2, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The Defense Logistics Agency awarded a $25,106.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, for the supply of EXPAREL 266 mg/20 mL vials. This delivery order, which carries an ultimate completion date of August 21, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November 2026. The award was made without set-aside designation, allowing DMS Pharmaceutical Group...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,521.66 to DMS Pharmaceutical Group Inc. for the supply of EXPAREL 133mg/10ml (10 units). The award was issued on August 7, 2025, with an ultimate completion date of August 26, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery from its Park Ridge location. This delivery order carries no set-aside designation...
- The Defense Logistics Agency awarded a $19,662.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 26, 2025, for the supply of EXPAREL 266 mg/20 ml vials. The order, with an ultimate completion date of October 20, 2025, represents a continuation of the agency's pharmaceutical supply chain operations. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, competing...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, valued at $15,063.78 with an ultimate completion date of October 9, 2025, was issued without a set-aside designation. The award leverages DMS Pharmaceutical Group's position as a critical supplier within the federal pharmaceutical supply...
- The Defense Logistics Agency (DLA), operating under the Department of Defense, awarded a delivery order valued at $35,148.82 to DMS Pharmaceutical Group Inc. on September 23, 2025, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order is expected to be completed by October 15, 2025, with fulfillment from the vendor's location in Park Ridge, Illinois. The contract does not utilize a set-aside designation, allowing DMS Pharmaceutical Group to compete on a competitive...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,553.15 to DMS Pharmaceutical Group Inc. for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 ml vials. This award, issued on September 23, 2025, with an ultimate completion date of October 15, 2025, represents a single delivery order without set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the...
- The Defense Logistics Agency awarded a delivery order valued at $25,106.30 to DMS Pharmaceutical Group Inc. for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 ml vials on August 28, 2025. This firm fixed-price delivery order, with an ultimate completion date of September 19, 2025, will be fulfilled from the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB26FX1KRDelivery Order
The Defense Logistics Agency (DLA) awarded a $20,085.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is the sole awardee with no identified subcontractors on this transaction. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense healthcare operations globally. EXPAREL is a specialty surgical anesthetic product that aligns with the vendor's established portfolio of branded pharmaceuticals, biologics, and medical consumables serving military healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.1k | 10/31/25 |